Abstract: The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO inhuman cells, and a method for the large technical production of EPO in human cells.

Abstract: Subject of the present invention are compounds of general formula (I), wherein A is oxygen or sulfur; X is oxygen or sulfur, R1 and R2 are independently hydrogen or an alkyl group with from 1 to 6 carbon atoms; R is selected from alkyl, cycloalkyl, alkylsulphinyl, alkylsulphonyl, hydroxyalkyl, napthtyl, phenyl group which can be unsubsituted or substituted; or R is a 5- or 6-membered heterocycle containing from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, which can be optionally benzocondensed, the pure steroisomers or mixtures thereof as well as salts thereof with pharmaceutically acceptable acids or bases, for the use as medicaments, in particular as antitumor agents.

Abstract: The invention concerns pharmaceutical forms of administration that are in the form of pellets which contain a retarding agent in which the release rate of the active substance is not delayed or is substantially identical compared to corresponding pellets that contain no retarding agent. The release rate of these rapidly disintegrating pellets is at least about 90% within a time period of 30 minutes. In addition the present invention also concerns processes for the production these pellets.

Abstract: The invention concerns a moisture-impermeable, tightly sealable storage container for use with a plurality of test elements. The storage container includes a housing sized to hold the test elements, a guide element, a spacer positioned between the guide element and a first test element to be withdrawn, and a transport mechanism for the test elements, the transport mechanism being positioned in the housing.

Abstract: The present invention is directed to a pharmaceutical combination preparation comprising 2,000-7,000 U of recombinant human erythropoietin (EPO) and 5-20 mg of an Fe(III) complex, wherein the rhEPO and the Fe(III) complex may be present in separate administration forms or in an integrated administration form.

Abstract: An immunoassay for the determination of myocardial necroses using antibodies to troponin T and a binding partner B for troponin T or for the an antibody, whereby either the antibody or the binding partner B is labelled with a determinable group. The immunological complex formed which contains the determinable group is isolated by separation of the phases and the determinable group is determined in one of the phases. Furthermore, monoclonal and polyclonal antibodies to troponin T are described with a cross-reactivity of less than 5% to skeletal muscle troponin T and less than 2% to troponin I and other myofibrillar proteins.

Abstract: The present invention is concerned with the use of individual administration forms of an erythropoietin preparation and a physiologically compatible iron preparation corresponding to an equivalent amount of 1-40 mg of iron ions for the production of a pharmaceutical combination preparation for the treatment of rheumatic diseases.

Abstract: The invention concerns an immunological process for the determination of prostate-specific antigen (PSA), particularly for the determination of free PSA, the total concentration of PSA and the concentration of PSA-serpin complexes by incubation of the sample with at least one antibody specifically binding to free PSA but not to complex PSA. The process is characterized in that especially before the determination of the total PSA concentration a nucleophile containing amine is added to the sample. Furthermore, the invention concerns the use of amine-containing nucleophiles for the production of free PSA as well as a procedure for preparing free PSA from complex PSA by incubation of a sample containing complex PSA with a nucleophile containing amine.

Abstract: Method and device for checking the liquid take up of a test layer of an analysis element. The test layer is absorbent and takes up a liquid when an analysis is carried out. The test layer is illuminated with primary light to generate a light signal characteristic of the liquid take up. Secondary light emerging here from the analysis element is detected. The test layer is in contact with an optically transparent foil segment. Reliably checking liquid take up is achieved by detecting secondary light emerging from the circumferential surface of the foil.

Abstract: A novel rec-L-N-carbamoylase from Arthrobacter aurescens and its method of use for producing L-amino acids. The recombinantly produced L-carbamoylase is unexpectedly stable, so that an industrial method of producing L-amino acids can be established with it, in contrast to previously known L-carbamoylases.

Abstract: The invention concerns parenteral pharmaceutical forms of administration containing polypeptide in the form of microparticles and a process for the production thereof. The microparticles according to the invention contain as a biodegradable polymer an ABA triblock copolymer the A block of which is a copolymer of lactic and glycolic acid and the B block of which represents a polyethylene glycol chain, together with additives that are selected from the group comprising serum proteins, polyamino acids, cyclodextrins, cyclodextrin derivatives, saccharides, amino sugars, amino acids, detergents or carboxylic acids as well as mixtures of these additives. The microparticles according to the invention continuously release the polypeptide over a relatively long time period even when the amounts of polypeptide they include are small or susceptible to aggregation.

Abstract: The invention concerns a method of purifying extrachromosomal DNA by passing an extrachromosomal DNA and fluid containing further cell components through a cross-flow centrifuge under given conditions, resulting in separation of the extrachromosomal DNA from the other cell components such that purified extrachromosomal DNA is obtained. The invention further concerns the use of the purified extrachromosomal DNA for cloning, transformation, transfection and microinjection into cells, for use in gene therapy processes, DNA vaccination and/or for polymerase chain reaction (PCR). The invention finally concerns the use of a cross-flow centrifuge for purifying extrachromosomal DNA.

Abstract: A nucleic acid molecule (URIM) with the nucleic acid sequence SEQ ID NO:1 is capable of inducing tumor progression and/or metastasis. The URIM protein of SEQ ID NO:2 is also provided. A process for determining whether a tumor sample has metastatic potential is provided.

Abstract: The invention relates to a method for forming a mixed disulfide of recombinant proteins, by solubilizing with a denaturing agent in the presence of a disulphide component, and then adding a disulphide component plus a denaturing agent, at a concentration sufficient to form a mixed disulfide.

Abstract: Erythropoietin glycoprotein products are disclosed which have the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells. The present conjugates have an increased circulating half-life and plasma residence time, decreased clearance, and increased clinical activity in vivo. In addition, compared with conventional PEG-EPO conjugates, the conjugates of this invention have superior clinical properties. The present invention also includes a method for the treatment of anemia in a human employing the novel erythropoietin glycoprotein products as well as a method for preparing the erythropoietin glycoprotein products.

Abstract: The invention concerns a new immunoregulatory protein LST-1, nucleic acd sequences coding for this protein, a process for the isolation of this protein, as well as its use for the production of a therapeutic agent. The DNA and protein sequences are shown in SEQ ID NO:1 to 4.

Abstract: The invention concerns a method for the immunological determination of an analyte on a chromatographic test strip containing one or several absorbent matrices on a carrier material which are in liquid-transferring contact with one another wherein the matrices form an application zone at one end and a suction zone at the other end of the carrier material, a conjugate zone in the application zone or adjoining the application zone which contains a visually detectable, particle-labelled analyte binding partner, a chromatographic zone adjoining the conjugate zone and a capture zone between the chromatographic zone and suction zone wherein the capture zone contains solid phase-bound binding partners for the analyte or for an unlabelled analyte-specific binding partner by applying the analyte solution to the application zone and measuring the bound label in the capture zone as a measure of the analyte characterized in that a fluorescent dye is applied to the application zone or to a matrix between the application zo

Abstract: The invention is directed to barbituric acid derivatives having inhibitory activity for matrix maetalloproteases comprised of formula (I): pharmaceutical compositions thereof, processes for preparing the derivatives, and methods for treating diseases associated with elevated or uncontrolled levels of matrix metalloprotease activity, e.g., cancer, specifically tumor progression and tumor metastasis, inflammation, or as a method of contraception.

Abstract: An immunoassay for the determination of myocardial necroses using antibodies to troponin T and a binding partner B for troponin T or for the an antibody, whereby either the antibody or the binding partner B is labelled with a determinable group. The immunological complex formed which contains the determinable group is isolated by separation of the phases and the determinable group is determined in one of the phases. Furthermore, monoclonal and polyclonal antibodies to troponin T are described with a cross-reactivity of less than 5% to skeletal muscle troponin T and less than 2% to troponin I and other myofibrillar proteins.

Abstract: The invention concerns a process for increasing the formation of the natural protein conformation when disulfide-bonded proteins are secreted by a prokaryotic host organism that contains a recombinant DNA coding for the secreted protein whereby the host organism is cultured in a suitable culture medium under suitable conditions for the expression of the recombinant DNA, which is characterized in that a culture medium containing 0.1 to 20 mmol/l of one or several thiol reagents is used.